Europe Syringe Infusion Pump Market Size, Share & Trends Analysis Report By Disease Indication (Chemotherapy, Gastroenterology, Hematology), By End-use, By Country, And Segment Forecasts, 2025 - 2030

Europe Syringe Infusion Pump Market Trends

The Europe syringe infusion pumps market size was estimated at USD 465.1 million in 2024 and is projected to grow at a CAGR of 7.9% from 2025 to 2030. Growing adoption across intensive care units, especially for pediatric treatments, is primarily driven by the precision offered by the product, compatibility with various applications, and ease of use.

Syringe infusion pumps reduce human error and ensure accurate dosing, which leads to improved patient outcomes. Increasing emphasis on offering quality care and patient safety, as well as incorporating technology-assisted equipment in the healthcare sector, is expected to fuel growth during the forecast period.

The increasing prevalence of chronic diseases across Europe has resulted in a growing adoption of technology-powered devices and equipment within the healthcare sector. Healthcare professionals prefer these devices for treating patients in pediatrics, neonatal care, chronic illnesses, and other complex health conditions. These situations often require controlled delivery of medications and precise dosing, which play a significant role in patient outcomes. Syringe infusion pumps effectively solve such problems with key features such as precise performance, compact size, user-friendly operations, real-time monitoring capabilities, and more.

In recent years, Europe has experienced a substantial increase in incidence related to numerous health conditions. For instance, nearly 500,000 premature births are recorded in Europe each year, and premature birth is one of the key causes of fatality in children under the age of 5 across the region. The growing incidence rate of such health issues has increased the utilization of sophisticated devices and equipment such as syringe infusion pumps.

Significant growth in hospitalizations, especially in intensive care units, originating from chronic diseases such as cancer, diabetes, cardiovascular diseases, respiratory disorders, and traumatic injuries, is anticipated to drive growth for this market. According to the European Cancer Organization, 300,000 EU citizens are diagnosed with hematological malignancy, including leukemia and lymphoma. The increasing incidence of blood disorders in Europe, significant growth in premature births, and growing adoption of syringe infusion pumps for controlled delivery of fluids and medications in cases where oral administration is not feasible are projected to create additional growth opportunities.

Disease Indication Insights

The pediatrics/neonatology segment led the market with the largest revenue share of 26.2% in 2024. A growing number of premature births in the region and the use of syringe infusion pumps by healthcare professionals for controlled delivery of IV anesthetic drugs, fluids, dextrose, and other medications are primarily driving the growth of this segment. Infants' Sensitivity to drugs and risks associated with dosing and delivery necessitate using equipment such as syringe infusion pumps. The emergence of technologies such as Dose Error Reduction Software (DERS) facilitates the growing adoption. In addition, the presence of stringent European Union regulations, such as The Paediatric Regulation (EC), also leads to the use of efficient systems and medical devices that ensure the safety of patients.

The chemotherapy segment is anticipated to grow at the fastest CAGR of 8.8% over the forecast period. Syringe infusion pumps are primarily used for controlled delivery of chemotherapy drugs and administration of multiple medications related to palliative care simultaneously run during the chemotherapy. Minimizing side effects and early integration of palliative care with chemotherapy are vital in improving patient outcomes. Europe has experienced nearly a 60.0% increase in newly diagnosed cancer cases since 1995, and cancer is likely to become the leading cause of death in Europe by 2035. The rising prevalence of cancer and growing focus on the integration of palliative care during chemotherapy are expected to drive the growth of this segment.

End Use Insights

The hospitals segment accounted for the largest market revenue share in 2024. Hospitals offer various healthcare services associated with critical care, palliative care, neonatal care, oncology, and more, which require the use of technology-driven devices such as syringe infusion pumps to ensure reduced error and improved patient outcomes. The growing scope of applications, including chemotherapy, pain management, cardiovascular diseases, gastrointestinal disorders, infant care, and others, is expected to fuel adoption. The presence of skilled professionals equipped with the necessary know-how to operate such devices and a continuous increase in admission volume are expected to support the growth of this segment.

The homecare segment is projected to grow at the fastest CAGR of 8.7% over the forecast period. The rise in chronic diseases signifies the need for long-term care and adequate medication. This leads to increased interest in homecare syringe infusion pumps for safe therapy outside hospitals as healthcare shifts towards ambulatory and home-based care. User-friendly devices that facilitate ease of use and cost reductions are increasingly adopted in the region. Technological advancements, such as improved connectivity and remote monitoring capabilities, are expected to support growing adoption.

Country Insights

The syringe infusion pumps market in Germany accounted for the largest market revenue share of 24.06% in Europe in 2024. The robust manufacturing industry active in the country, the presence of multiple manufacturers of syringe infusion pumps in Germany, the growing focus of healthcare services providers on delivering technology-supported care, and increasing adoption driven by growing cases of chronic diseases are fueling the growth. In recent years, Germany has experienced a large number of new cases associated with breast cancer, prostate cancer, colon cancer, and lung cancer. In addition, nearly 8.5 million individuals are diagnosed with diabetes in Germany. Growth in the incidence rate of such diseases is expected to generate greater adoption of syringe infusion pumps in Germany over the forecast period.

The France syringe infusion pumps market is expected to experience at the fastest CAGR from 2025 to 2030. France has been implementing numerous strategies and screening programs to ensure early detection and improved treatment of cancer in the country. For instance, Stratégie Décennale de lutte contre les cancers 2021-2030, a ten-year cancer strategy was launched to initiate primary and secondary cancer prevention in the country. This has led to the growing adoption of palliative care measures and efforts to reduce mortality and enhance patient outcomes.

Key Europe Syringe Infusion Pump Company Insights

Key players in the Europe syringe infusion pumps industry include B. Braun SE, Fresenius Kabi AG, Micrel Medical Devices SA, CODAN Companies, Arcomed and others. The major players focus on innovation, collaborations, and growth through acquisitions and mergers to address competition and increasing adoption.

• B. Braun SE is a medical technology company that provides various healthcare products and services for diabetes care, extracorporeal blood treatment, neurosurgery, nutrition, ostomy surgery, and more. It offers an extensive range of infusion pumps and accessories, including the Perfusor range.

• Fresenius Kabi AG is a healthcare company operating in therapeutic areas such as anesthesia, biosimilar, oncology, renal, and liver insufficient. It also manufactures infusion pumps for fluid management, critical illness, and blood volume substitutions.

Recent Developments

• In December 2023, Fresenius Kabi announced it had entered a multi-year agreement with the Mayo Clinic, with the expected purchase of nearly 10,000 units of Ivenix large-volume infusion pumps. This has strengthened its strategic efforts to expand the adoption of its advanced technology-based devices.

• In February 2023,Mindray, a medical technology company, launched the BeneFusion i/u Series infusion systems. These new-generation technology-powered systems have added to the company's portfolio of safe medication innovation technologies. 

Europe Syringe Infusion Pumps Market Report Scope

Europe Syringe Infusion Pump Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the Europe syringe infusion pumps market report based on disease indication, end use, and country:

• Disease Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Chemotherapy

  • Diabetes

  • Gastroenterology

  • Analgesia/Pain Management

  • Pediatrics/Neonatology

  • Hematology

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Homecare

  • Others (ASC, Nursing Homes, Rehabilitation Centers)

• Country Outlook (Revenue, USD Million, 2018 - 2030)

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Norway

  • Sweden